Amgen Announces New Data from Phase 2 BLINCYTOa Immunotherapy Study in Patients with Acute Lymphoblastic Leukemia and Minimal Residual Disease Amgen today announced new data from the Phase 2 BLAST study which evaluated the bispecific T cell engager immunotherapy BLINCYTOa in patients with minimal residual disease positive B-cell precursor acute lymphoblastic leukemia . In the study, 78 percent of patients who received BLINCYTO experienced a complete MRD response , a measure of eradication of residual disease at the molecular level, after one treatment cycle.
http://ift.tt/1zAmmIJ
http://ift.tt/1zAmmIJ
No comments:
Post a Comment